The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough to gauge which innovative biotech firms will have…
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five…
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may…
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes it much easier.
Chris Lange 24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus price target.
Chris Lange The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference (May 31…
Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health care stocks — biotechs specifically — are blowing these tech stocks out…
Chris Lange 24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how…
24/7 Wall St. has come up with its own view on earnings season by sector, along with relative performance on the top exchange traded funds for those sectors.
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
Jon C. Ogg Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming…
